Influence of ezetimibe on selected parameters of oxidative stress in rat liver subjected to ischemia/reperfusion

Archives of Medical Science

Volumn 10, Issue 4, 2014, Pages 817-824

  Trocha, Małgorzata ^a   Merwid Laḑ, Anna ^a   Chlebda, Ewa ^a   Sozanśki, Tomasz ^a   Pieśniewska, Małgorzata ^a   Gliniak, Halina ^a   Szelaģ, Adam ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Ischemia reperfusion; Liver; Oxidative stress; Rat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EZETIMIBE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; LIVER HOMOGENATE; LIVER INJURY; LIVER ISCHEMIA; LIVER PROTECTION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REPERFUSION INJURY; TREATMENT DURATION;

EID: 84907450695     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2013.38087     Document Type: Article

References (61)

1. Cobreros A, Sainz L, Lasheras B, Cenarruzabeitia E. Hepatotoxicity of ethanol: protective effect of calcium channel blockers in isolated hepatocytes. Liver 1997; 17: 76-82. (Pubitemid 27179980)
2. Fan C, Zwacka RM, Engelhardt JF. Therapeutic approaches for ischemia/reperfusion injury in the liver. J Mol Med 1999; 77: 577-96.
3. Hines IN, Harada H, Flores S, Gao B, McCord JM, Grisham MB. Endothelial nitric oxide synthase protects the post-ischemic liver: potential interactions with superoxide. Biomed Pharmacother 2005; 59: 183-9. (Pubitemid 40603331)
4. Scandalios JG. Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses. Braz J Med Biol Res 2005; 38: 995-1014. (Pubitemid 41078961)
5. Alan C, Kocoglu H, Altintas R, Alici B, Ersay AR. Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. Arch Med Sci 2011; 2: 211-6.
6. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004; 44: 381-6. (Pubitemid 39281479)
7. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs 2002; 62: 2333-47. (Pubitemid 35316384)
8. Gracia-Cavlo M, Lisnock JM, Bull HG, et al. The target of ezetimibe is Niemann-Pick C 1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102: 8132-7. (Pubitemid 40800055)
9. Habior A, Rawa T, Krawczyk M, et al. Liver transplantation - evaluation requirements, indications and rules for qualification [Polish]. Med Science Rev Hepatologia Med J For Cont, 85-90.
10. Jessani S, Watson T, Cappuccio FP, et al. Prevention of cardiovascular disease in clinical practice: the Joint British Societies' (JBS 2) guidelines. J Hum Hypertens 2006; 20: 641-5. (Pubitemid 44269854)
11. Kawecka-Jaszcz K, Jankowski P, Pajak A. Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease. Int J Cardiol 2003; 91: 15-23. (Pubitemid 37101095)
12. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587-95. (Pubitemid 40628813)
13. Pikto-Pietkiewicz W, Pasierski T. Ezetimibe - cholesterol absorption inhibitor [Polish]. Kardiol Pol 2006; 64: 1434-41.
14. Shekhar Pandey A, Bissonnette S, Boukas S, Rampakakis E, Sampalis JS. Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci 2011; 7: 767-75.
15. Rizzo M, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des 2013; 19: 3858-68.
16. Fukuda M, Nakamura T, Kataoka K, et al. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Therap 2010; 335: 70-5.
17. Nakagami H, Osako MK, Takami Y, et al. Vascular protective effects of ezetimibe in apoE-deficient mice. Atherosclerosis 2009; 203: 51-8.
18. Kurobe H, Aihara KI, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011; 18: 1080-9.
19. Yamaoka-Tojo M, Tojo T, Takahira N, Masuda T, Izumi T. Ezetimibe and reactive oxygen species. Curr Vasc Pharmacol 2011; 9: 109-20.
20. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology 2005; 104: 176-80. (Pubitemid 41407271)
21. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63. (Pubitemid 40647072)
22. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010; 633: 62-70.
23. Cheng Y, Liu F, Wu J, Zhang Y, Nilsson A, Duan RD. Ezetimibe inhibits expression of acid sphingomyelinase in liver and intestine. Lipids 2009; 44: 897-906.
24. Oswald S, May K, Rosin J, Lütjohann D, Siegmund W. Synergistic influence of Abcb1 and Abcc2 on dis position and sterol lowering effects of ezetimibe in rats. J Pharm Sci 2010; 99: 422-9.
25. Hayashi H, Kanai S, Yamada Y, Tsushima M, Miyasaka K. Acute inhibition of lymphatic cholesterol transport in rat intestine by SCH 58053. J Atheroscler Thromb 2006; 13: 240-6.
26. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 2006; 318: 1293-9. (Pubitemid 44268338)
27. Morales AI, Vicente-Sanchez C, Jerkic M, et al. Effect of quercetin on metallothionein, nitric oxide synthase and cyclooxygenase-2 expression on experimental chronic cadmium nephrotoxicity in rats. Toxicol Appl Pharmacol 2006; 210: 128-35. (Pubitemid 41790560)
28. Turfaner N, Uzun H, Balci H, et al. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med J 2010; 103: 428-33.
29. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1030-8.
30. Montalvo-Javé EE, García-Puig MA, Escalante-Tattersfield T, Peña-Sánchez J, Vázquez-Meza H, Ortega-Salgado JA. Biochemical analysis and lipid peroxidation in liver ischemic preconditioning. Cir Cir 2011; 79: 132-40.
31. Wu C, Wang P, Rao J, et al. Triptolide alleviates hepatic ischemia/reperfusion injury by attenuating oxidative stress and inhibiting NF-kappaB activity in mice. J Surg Res 2011; 166: e205-13.
32. Somuncu S, Cakmak M, Dikmen G, Akman H, Kaya M. Ischemia-reperfusion injury of rabbit ovary and protective effect of trapidil: an experimental study. Pediatr Surg Int 2008; 24: 315-8.
33. Turgut F, Bayrak O, Catal F, et al. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol 2008; 40: 453-60.
34. Ceylan A, Karasu C, Aktan F, Güven C, Can B, Ozansoy G. Effects of simvastatin treatment on oxidant/antioxidant state and ultrastructure of diabetic rat myocardium. Gen Physiol Biophys 2003; 22: 535-47. (Pubitemid 38324671)
35. Ozansoy G, Akin B, Aktan F, Karasu Ç. Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats. Mol Cell Biochem 2001; 216: 59-63. (Pubitemid 32142224)
36. Xue F, Zhang JJ, Xu LM, Zhang C, Xia Q. Protective effects of HGF-MSP chimer (metron factor-1) on liver ischemia-reperfusion injury in rat model. J Dig Dis 2010; 11: 299-305.
37. Jankowski P, Loster M, Kawecka-Jaszcz K. Ezetimibe: new perspectives in lipid lowering treatment. Cardiol J 2007; 14: 232-7. (Pubitemid 47249343)
38. Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007; 63: 113-21. (Pubitemid 46147052)
39. Ucak A, Onan B, Güler A, et al. Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats. Ann Vasc Surg 2011; 25: 686-95.
40. Krauss H, Sosnowski P, Biczysko M, et al. Effects of Larginine and NG-nitro L-arginine methyl ester (L-NAME) on ischemia/reperfusion injury of skeletal muscle, small and large intestines. Chin J Physiol 2011; 54: 7-18.
41. Shokeir AA, Barakat N, Hussein AA, Awadalla A, Abdel-Aziz A, Abo-Elenin H. Role of combination of L-arginine and alpha-tocopherol in renal transplantation ischaemia/reperfusion injury: a randomized controlled experimental study in a rat model. BJU Int 2011; 108: 612-8.
42. Stapleton PA, Goodwill AG, James ME, Brock RW, Frisbee JC. Hypercholesterolemia and microvascular dysfunction: interventional strategies. J Inflam 2010; 7: 1-10.
43. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2007; 65: 637-45. (Pubitemid 351535082)
44. Chan DC, Watts GF, Gan SK, Ooi EMM, Hugh P, Barrett R. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134-9.
45. Yamaoka-Tojo M, Tojo T, Kosugi R, et al. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipid Health Dis doi: 10.1186/1476-511X-8-41.
46. Kostapanos MS, Spyrou AT, Tellis CC, et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemia subjects with high oxidative stress. Lipids 2011; 46: 341-8.
47. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner Pharmacol Res 2010; 61: 58-61.
48. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-8.
49. Rizzo M, Rini GB. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Med Sci 2011; 7: 5-7.
50. Masuda T, Iwashita Y, Hagiwara S, et al. Dihydrolipoyl histidinate zinc complex, a new antioxidant, attenuates hepatic ischemia-reperfusion injury in rats. Gastroenterol Hepatol 2011; 26: 1652-8.
51. Evans ZP, Mandavilli BS, Ellett JD, et al. Vitamin E succinate enhances steatotic liver energy status and prevents oxidative damage following ischemia/reperfusion. Transplant Proc 2009; 41: 4094-8.
52. Castro AP, Castro Junior MA, Lauz S, Facin E, Simões Mde J, Fagundes DJ. The role of N-acetyl-cysteine in the lung remote injury after hepatic ischemia and reperfusion in rabbits. Acta Cir Bras 2012; 27: 49-55.
53. Fiorini RN, Donovan JL, Rodwell D, et al. Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transpl 2005; 11: 298-308. (Pubitemid 40458402)
54. Castellote J, Ariza J, Rota R, GirbauA, Xiol X. Serious drug-induced disease secondary to ezetimibe. World J Gastroenterol 2008; 14: 5098-9.
55. Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated with ezetimibe therapy. Dig Dis Sci 2007; 52: 602-5. (Pubitemid 46202848)
56. Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 2006; 4: 908-11. (Pubitemid 43994537)
57. Obermayer-Straub P, Strassburg CP, Manns MP. Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases. Can J Gastroenterol 2000; 14: 429-39. (Pubitemid 30339370)
58. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
59. Ogawa T, Fujii H, Yoshizato K, Kawada N. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol 2010; 177: 153-65.
60. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 2009; 15: 504-8.
61. Savvidaki E, Koukoulaki M, Benou A, et al. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients. Clin Nephrol 2011; 75: 107-12.